JP2020512288A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2020512288A5 JP2020512288A5 JP2019531811A JP2019531811A JP2020512288A5 JP 2020512288 A5 JP2020512288 A5 JP 2020512288A5 JP 2019531811 A JP2019531811 A JP 2019531811A JP 2019531811 A JP2019531811 A JP 2019531811A JP 2020512288 A5 JP2020512288 A5 JP 2020512288A5
- Authority
- JP
- Japan
- Prior art keywords
- fibrosis
- tissue
- collagen deposition
- plasminogen
- pharmaceutical composition
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 206010016654 Fibrosis Diseases 0.000 claims 25
- 230000004761 fibrosis Effects 0.000 claims 25
- 210000000056 organ Anatomy 0.000 claims 21
- 102000008186 Collagen Human genes 0.000 claims 14
- 108010035532 Collagen Proteins 0.000 claims 14
- 229920001436 collagen Polymers 0.000 claims 14
- 230000008021 deposition Effects 0.000 claims 14
- 239000008194 pharmaceutical composition Substances 0.000 claims 11
- 239000003814 drug Substances 0.000 claims 9
- 229940079593 drug Drugs 0.000 claims 9
- 102000013566 Plasminogen Human genes 0.000 claims 8
- 108010051456 Plasminogen Proteins 0.000 claims 8
- 239000000203 mixture Substances 0.000 claims 6
- 208000015181 infectious disease Diseases 0.000 claims 5
- 201000002793 renal fibrosis Diseases 0.000 claims 5
- 208000019425 cirrhosis of liver Diseases 0.000 claims 3
- 230000006378 damage Effects 0.000 claims 3
- 230000000302 ischemic effect Effects 0.000 claims 3
- 206010061218 Inflammation Diseases 0.000 claims 2
- 206010028980 Neoplasm Diseases 0.000 claims 2
- 239000002246 antineoplastic agent Substances 0.000 claims 2
- 230000001684 chronic effect Effects 0.000 claims 2
- 230000000694 effects Effects 0.000 claims 2
- 238000003912 environmental pollution Methods 0.000 claims 2
- 208000026278 immune system disease Diseases 0.000 claims 2
- 230000004054 inflammatory process Effects 0.000 claims 2
- 210000004072 lung Anatomy 0.000 claims 2
- 208000005069 pulmonary fibrosis Diseases 0.000 claims 2
- 230000005855 radiation Effects 0.000 claims 2
- 239000000126 substance Substances 0.000 claims 2
- 206010002556 Ankylosing Spondylitis Diseases 0.000 claims 1
- 201000001320 Atherosclerosis Diseases 0.000 claims 1
- 208000037157 Azotemia Diseases 0.000 claims 1
- 241000894006 Bacteria Species 0.000 claims 1
- 206010018367 Glomerulonephritis chronic Diseases 0.000 claims 1
- 241000711549 Hepacivirus C Species 0.000 claims 1
- 241000700721 Hepatitis B virus Species 0.000 claims 1
- 241000724675 Hepatitis E virus Species 0.000 claims 1
- 206010020751 Hypersensitivity Diseases 0.000 claims 1
- 201000009794 Idiopathic Pulmonary Fibrosis Diseases 0.000 claims 1
- 208000008839 Kidney Neoplasms Diseases 0.000 claims 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims 1
- 241000187479 Mycobacterium tuberculosis Species 0.000 claims 1
- 206010029164 Nephrotic syndrome Diseases 0.000 claims 1
- 102000001938 Plasminogen Activators Human genes 0.000 claims 1
- 108010001014 Plasminogen Activators Proteins 0.000 claims 1
- 206010037596 Pyelonephritis Diseases 0.000 claims 1
- 208000001647 Renal Insufficiency Diseases 0.000 claims 1
- 206010038389 Renal cancer Diseases 0.000 claims 1
- 206010050207 Skin fibrosis Diseases 0.000 claims 1
- 201000009594 Systemic Scleroderma Diseases 0.000 claims 1
- 206010042953 Systemic sclerosis Diseases 0.000 claims 1
- 241000700605 Viruses Species 0.000 claims 1
- 230000003288 anthiarrhythmic effect Effects 0.000 claims 1
- 239000003242 anti bacterial agent Substances 0.000 claims 1
- 239000003416 antiarrhythmic agent Substances 0.000 claims 1
- 239000003146 anticoagulant agent Substances 0.000 claims 1
- 229940127219 anticoagulant drug Drugs 0.000 claims 1
- 239000003472 antidiabetic agent Substances 0.000 claims 1
- 239000002220 antihypertensive agent Substances 0.000 claims 1
- 229940030600 antihypertensive agent Drugs 0.000 claims 1
- 239000003524 antilipemic agent Substances 0.000 claims 1
- 229940127218 antiplatelet drug Drugs 0.000 claims 1
- 239000003443 antiviral agent Substances 0.000 claims 1
- 230000001363 autoimmune Effects 0.000 claims 1
- 230000003115 biocidal effect Effects 0.000 claims 1
- 210000004204 blood vessel Anatomy 0.000 claims 1
- 201000011510 cancer Diseases 0.000 claims 1
- 230000000747 cardiac effect Effects 0.000 claims 1
- 238000006243 chemical reaction Methods 0.000 claims 1
- 239000003795 chemical substances by application Substances 0.000 claims 1
- 208000029078 coronary artery disease Diseases 0.000 claims 1
- 229940127089 cytotoxic agent Drugs 0.000 claims 1
- 201000010099 disease Diseases 0.000 claims 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 1
- 239000002934 diuretic Substances 0.000 claims 1
- 229940030606 diuretics Drugs 0.000 claims 1
- 239000000835 fiber Substances 0.000 claims 1
- 239000003527 fibrinolytic agent Substances 0.000 claims 1
- -1 for example Substances 0.000 claims 1
- 239000012634 fragment Substances 0.000 claims 1
- 230000002443 hepatoprotective effect Effects 0.000 claims 1
- 229940126904 hypoglycaemic agent Drugs 0.000 claims 1
- 239000002955 immunomodulating agent Substances 0.000 claims 1
- 229940121354 immunomodulator Drugs 0.000 claims 1
- 230000002757 inflammatory effect Effects 0.000 claims 1
- 239000004041 inotropic agent Substances 0.000 claims 1
- 208000036971 interstitial lung disease 2 Diseases 0.000 claims 1
- 208000028867 ischemia Diseases 0.000 claims 1
- 201000010982 kidney cancer Diseases 0.000 claims 1
- 201000006370 kidney failure Diseases 0.000 claims 1
- 230000003902 lesion Effects 0.000 claims 1
- 210000004185 liver Anatomy 0.000 claims 1
- 201000007270 liver cancer Diseases 0.000 claims 1
- 208000014018 liver neoplasm Diseases 0.000 claims 1
- 201000005202 lung cancer Diseases 0.000 claims 1
- 208000020816 lung neoplasm Diseases 0.000 claims 1
- 108010087750 lysyl-plasminogen Proteins 0.000 claims 1
- 108010049112 miniplasminogen Proteins 0.000 claims 1
- 244000045947 parasite Species 0.000 claims 1
- 229940127126 plasminogen activator Drugs 0.000 claims 1
- 239000000106 platelet aggregation inhibitor Substances 0.000 claims 1
- 230000002265 prevention Effects 0.000 claims 1
- 102000004169 proteins and genes Human genes 0.000 claims 1
- 108090000623 proteins and genes Proteins 0.000 claims 1
- 230000000717 retained effect Effects 0.000 claims 1
- 201000004409 schistosomiasis Diseases 0.000 claims 1
- 230000009885 systemic effect Effects 0.000 claims 1
- 201000000596 systemic lupus erythematosus Diseases 0.000 claims 1
- 238000002560 therapeutic procedure Methods 0.000 claims 1
- 229960000103 thrombolytic agent Drugs 0.000 claims 1
- 230000000451 tissue damage Effects 0.000 claims 1
- 231100000827 tissue damage Toxicity 0.000 claims 1
- 208000009852 uremia Diseases 0.000 claims 1
- 229940124549 vasodilator Drugs 0.000 claims 1
- 239000003071 vasodilator agent Substances 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2016110174 | 2016-12-15 | ||
| CNPCT/CN2016/110174 | 2016-12-15 | ||
| PCT/CN2017/089058 WO2018107698A1 (zh) | 2016-12-15 | 2017-06-19 | 一种预防和治疗组织器官纤维化的方法 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2020512288A JP2020512288A (ja) | 2020-04-23 |
| JP2020512288A5 true JP2020512288A5 (https=) | 2020-07-30 |
| JP7313058B2 JP7313058B2 (ja) | 2023-07-24 |
Family
ID=62557850
Family Applications (4)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019531811A Active JP7313058B2 (ja) | 2016-12-15 | 2017-06-19 | 組織器官の繊維化を予防及び治療するための方法 |
| JP2019531808A Active JP7213553B2 (ja) | 2016-12-15 | 2017-06-19 | 肺の繊維化を予防及び治療するための方法 |
| JP2019531805A Active JP7213552B2 (ja) | 2016-12-15 | 2017-06-19 | 肝の繊維化を予防及び治療するための方法 |
| JP2019531806A Pending JP2020502132A (ja) | 2016-12-15 | 2017-06-19 | 皮膚の繊維化を予防及び治療するための方法 |
Family Applications After (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019531808A Active JP7213553B2 (ja) | 2016-12-15 | 2017-06-19 | 肺の繊維化を予防及び治療するための方法 |
| JP2019531805A Active JP7213552B2 (ja) | 2016-12-15 | 2017-06-19 | 肝の繊維化を予防及び治療するための方法 |
| JP2019531806A Pending JP2020502132A (ja) | 2016-12-15 | 2017-06-19 | 皮膚の繊維化を予防及び治療するための方法 |
Country Status (7)
| Country | Link |
|---|---|
| US (4) | US11154595B2 (https=) |
| EP (4) | EP3556382A4 (https=) |
| JP (4) | JP7313058B2 (https=) |
| CN (4) | CN110191718A (https=) |
| CA (3) | CA3046671C (https=) |
| TW (6) | TWI657823B (https=) |
| WO (5) | WO2018107694A1 (https=) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11154595B2 (en) | 2016-12-15 | 2021-10-26 | Talengen International Limited | Method for preventing and treating pulmonary fibrosis |
| CA3067890A1 (en) | 2017-06-19 | 2018-12-27 | Talengen International Limited | Method for regulating and controling glp-1/glp-1r and drug |
| TWI868051B (zh) * | 2017-06-23 | 2025-01-01 | 美商波麥堤克生物治療股份有限公司 | 與pai-1過表現相關之病狀的纖維蛋白溶酶原治療 |
| CA3167593A1 (en) * | 2020-02-11 | 2021-08-19 | Jinan Li | Method and drug for treating viral pneumonia |
| TWI910217B (zh) * | 2020-08-20 | 2026-01-01 | 大陸商深圳瑞健生命科學研究院有限公司 | 一種治療腫瘤的方法和藥物 |
| CN114984032B (zh) * | 2022-06-27 | 2023-07-07 | 四川大学 | Dna四面体框架核酸-绿原酸复合物及其在制备治疗肝纤维化的药物中的用途 |
Family Cites Families (52)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3773919A (en) | 1969-10-23 | 1973-11-20 | Du Pont | Polylactide-drug mixtures |
| IE52535B1 (en) | 1981-02-16 | 1987-12-09 | Ici Plc | Continuous release pharmaceutical compositions |
| US4645668A (en) | 1983-08-04 | 1987-02-24 | Biospecifics, Nv | Method for the prevention and treatment of scars with enzymes |
| GB8721951D0 (en) | 1987-09-18 | 1987-10-28 | Thrombosis Research Trust | Organic compounds |
| CA2226575C (en) | 1995-07-27 | 2011-10-18 | Genentech, Inc. | Stabile isotonic lyophilized protein formulation |
| WO1997041824A2 (en) | 1996-05-03 | 1997-11-13 | Abbott Laboratories | Antiangiogenic peptides derived from plasminogen |
| EP1001985A1 (en) | 1997-06-26 | 2000-05-24 | Karolinska Innovations AB | Kringle domains 1-5 of plasminogen, capable of modulating angiogenesis in vivo |
| AU5571799A (en) * | 1998-08-20 | 2000-03-14 | University Of Vermont And State Agricultural College, The | Angiogenesis inhibitors and uses thereof |
| US7763580B2 (en) | 1999-01-05 | 2010-07-27 | University Of Utah Research Foundation | Methods for treating conditions associated with the accumulation of excess extracellular matrix |
| US20030054988A1 (en) * | 2000-11-02 | 2003-03-20 | Weidong-Richard Ji | Modified plasminogen related peptide fragments and their use as angiogenesis inhibitors |
| MXPA00011713A (es) | 2000-11-28 | 2002-05-31 | Tgt Lab S A De C V | Vectores recombinantes virales y no virales conteniendo el gen humano del activador de plasminogeno derivado de urocinasa y su utilidad en el tratamiento de diversos tipos de fibrosis hepatica, renal, pulmonar, pancreatica, cardiaca y cicatrices hipe |
| US7067492B2 (en) | 2001-09-06 | 2006-06-27 | Omnio Ab | Method of promoting healing of a tympanic membrane perforation |
| DE10390418D2 (de) * | 2002-02-06 | 2005-01-13 | N Zyme Biotec Gmbh | Verfahren zur Herstellung von rekombinanten Proteinen in Mikroorganismen |
| AU2003210137A1 (en) * | 2002-02-06 | 2003-09-02 | N-Zyme Biotec Gmbh | Method for producing recombinant proteins in micro-organisms |
| EP1509236A4 (en) | 2002-05-13 | 2008-07-30 | Children S Hospital Los Angele | TREATMENT AND PREVENTION OF ABNORMAL SCALING IN KELOIDS AND OTHER SKIN OR INTERNAL WOUNDS OR LESIONS |
| BR0316583A (pt) | 2002-12-10 | 2005-10-04 | Wyeth Corp | Derivados de ácido acético 3-alquil e 3-arilalquil 1h-indol-1-il substituìdo como inibidores do inibidor-1 do ativador do plasminogênio (pai-1) |
| US20050250694A1 (en) | 2003-10-10 | 2005-11-10 | Ma Jian-Xing | Compounds useful in inhibiting vascular leakage, inflammation and fibrosis and methods of making and using same |
| JP2008510814A (ja) | 2004-08-23 | 2008-04-10 | ワイス | Ｐａｉ−１阻害剤としてのピロロ−ナフチル酸 |
| AU2007290881B2 (en) | 2006-08-28 | 2013-03-07 | Omnio Healer Ab | Candidates against infection |
| US20100080773A1 (en) | 2008-09-26 | 2010-04-01 | Sdg, Inc. | Orally Bioavailable Lipid-Based Constructs |
| PL2220221T3 (pl) | 2007-11-29 | 2015-07-31 | Grifols Therapeutics Inc | Rekombinacyjnie zmodyfikowana plazmina |
| WO2009111625A2 (en) * | 2008-03-05 | 2009-09-11 | Board Of Regents, The University Of Texas System | Peptide inhibition of lung epithelial apoptosis and pulmonary fibrosis |
| WO2011004011A1 (en) | 2009-07-10 | 2011-01-13 | Thrombogenics Nv | Variants of plasminogen and plasmin |
| CN101628113B (zh) | 2009-08-18 | 2012-01-04 | 南京农业大学 | 蚯蚓纤溶酶抗肝纤维化的应用 |
| NZ600160A (en) | 2009-11-07 | 2014-05-30 | Astute Medical Inc | Methods and compositions for diagnosis and prognosis of renal injury and renal failure |
| WO2011139974A2 (en) * | 2010-05-03 | 2011-11-10 | Abbott Laboratories | Anti-pai-1 antibodies and methods of use thereof |
| CN102121023B (zh) | 2010-12-22 | 2012-07-04 | 中山大学 | 突变型人纤溶酶原kringle5及其制备方法及应用 |
| JP6085568B2 (ja) | 2011-01-05 | 2017-02-22 | スロンボジェニックス・ナムローゼ・フェンノートシャップＴｈｒｏｍｂｏＧｅｎｉｃｓ ＮＶ | プラスミノーゲンおよびプラスミンの変異体 |
| CN102154253A (zh) | 2011-01-06 | 2011-08-17 | 郑州大学 | 具有抑制血小板凝集功能的微小纤溶酶原突变体及其制备方法和用途 |
| EP3593861B1 (en) | 2012-03-09 | 2022-12-14 | Vascular Biosciences | Combination of car peptide and a vasodilator for treating pulmonary hypertension |
| KR101467109B1 (ko) | 2013-07-10 | 2014-12-01 | 영남대학교 산학협력단 | Ｂｉｘ02189 화합물을 유효성분으로 포함하는 폐섬유증 예방 또는 치료용 조성물 |
| TN2016000048A1 (en) | 2013-08-13 | 2017-07-05 | Sanofi Sa | Antibodies to plasminogen activator inhibitor-1 (pai-1) and uses thereof |
| CN104371019B (zh) | 2013-08-13 | 2019-09-10 | 鸿运华宁（杭州）生物医药有限公司 | 一种能与glp-1r特异性结合的抗体及其与glp-1的融合蛋白质 |
| TW201734054A (zh) | 2013-08-13 | 2017-10-01 | 賽諾菲公司 | 胞漿素原活化素抑制劑-１（ｐａｉ-１）之抗體及其用途 |
| WO2015026494A2 (en) | 2013-08-20 | 2015-02-26 | Trustees Of Dartmouth College | Methods for treating tissue fibrosis |
| CA2939897A1 (en) | 2014-02-21 | 2015-08-27 | Astellas Pharma Inc. | New anti-human pai-1 antibody |
| PY1577621A (es) | 2014-12-19 | 2017-10-02 | Prometic Biotherapeutics Inc | Composicion farmaceutica que comprende plasminogeno y uso para el mismo |
| TWI801331B (zh) * | 2015-11-03 | 2023-05-11 | 美商波麥堤克生物治療股份有限公司 | 纖維蛋白溶酶原缺乏症之纖維蛋白溶酶原替代療法 |
| TWI624268B (zh) | 2015-12-18 | 2018-05-21 | Talengen Institute Of Life Sciences Co Ltd | 纖溶酶原在製備藥劑上的用途及包括纖溶酶原之藥劑 |
| CN106890320A (zh) | 2015-12-18 | 2017-06-27 | 深圳瑞健生命科学研究院有限公司 | 一种用于预防或治疗急性及慢性血栓的方法 |
| WO2017101873A1 (zh) | 2015-12-18 | 2017-06-22 | 深圳瑞健生命科学研究院有限公司 | 一种预防或治疗放射性和化学性损伤的方法 |
| CA3008185C (en) | 2015-12-18 | 2024-01-16 | Talengen International Limited | Method for prevention or treatment of acute and chronic thrombosis |
| CN106890324A (zh) | 2015-12-18 | 2017-06-27 | 深圳瑞健生命科学研究院有限公司 | 一种预防和治疗糖尿病肾病的方法 |
| CN106890318A (zh) | 2015-12-18 | 2017-06-27 | 深圳瑞健生命科学研究院有限公司 | 一种预防和治疗糖尿病性心脏病的新方法 |
| WO2017101867A1 (zh) | 2015-12-18 | 2017-06-22 | 深圳瑞健生命科学研究院有限公司 | 一种预防或治疗糖尿病性神经损伤及其相关病症的方法 |
| EP3556386A4 (en) | 2016-12-15 | 2020-07-08 | Talengen International Limited | METHOD FOR PREVENTING AND TREATING MEDICINALLY INDUCED KIDNEY INJURY |
| US11207387B2 (en) | 2016-12-15 | 2021-12-28 | Talengen International Limited | Method and drug for preventing and treating obesity |
| WO2018107707A1 (zh) | 2016-12-15 | 2018-06-21 | 深圳瑞健生命科学研究院有限公司 | 一种改善心脏病变的方法 |
| WO2018107688A1 (zh) | 2016-12-15 | 2018-06-21 | 深圳瑞健生命科学研究院有限公司 | 一种预防和治疗脂肪肝的方法 |
| JP7175270B2 (ja) | 2016-12-15 | 2022-11-18 | タレンゲン インターナショナル リミテッド | グルカゴン、インスリンを正常なバランスに戻らせる方法 |
| US11154595B2 (en) | 2016-12-15 | 2021-10-26 | Talengen International Limited | Method for preventing and treating pulmonary fibrosis |
| CA3067890A1 (en) | 2017-06-19 | 2018-12-27 | Talengen International Limited | Method for regulating and controling glp-1/glp-1r and drug |
-
2017
- 2017-06-19 US US16/470,179 patent/US11154595B2/en active Active
- 2017-06-19 WO PCT/CN2017/089054 patent/WO2018107694A1/zh not_active Ceased
- 2017-06-19 US US16/470,172 patent/US11219669B2/en active Active
- 2017-06-19 CN CN201780078169.0A patent/CN110191718A/zh active Pending
- 2017-06-19 JP JP2019531811A patent/JP7313058B2/ja active Active
- 2017-06-19 JP JP2019531808A patent/JP7213553B2/ja active Active
- 2017-06-19 TW TW106120449A patent/TWI657823B/zh active
- 2017-06-19 TW TW106120456A patent/TWI670075B/zh active
- 2017-06-19 WO PCT/CN2017/089056 patent/WO2018107696A1/zh not_active Ceased
- 2017-06-19 EP EP17880398.7A patent/EP3556382A4/en active Pending
- 2017-06-19 TW TW106120453A patent/TWI734798B/zh active
- 2017-06-19 CA CA3046671A patent/CA3046671C/en active Active
- 2017-06-19 WO PCT/CN2017/089058 patent/WO2018107698A1/zh not_active Ceased
- 2017-06-19 EP EP17881523.9A patent/EP3556389A4/en active Pending
- 2017-06-19 WO PCT/CN2017/089057 patent/WO2018107697A1/zh not_active Ceased
- 2017-06-19 TW TW110101502A patent/TW202123955A/zh unknown
- 2017-06-19 CN CN201780078123.9A patent/CN110114080A/zh active Pending
- 2017-06-19 US US16/470,162 patent/US20190314466A1/en not_active Abandoned
- 2017-06-19 US US16/470,186 patent/US11071772B2/en active Active
- 2017-06-19 JP JP2019531805A patent/JP7213552B2/ja active Active
- 2017-06-19 EP EP17882248.2A patent/EP3556395A4/en active Pending
- 2017-06-19 WO PCT/CN2017/089053 patent/WO2018107693A1/zh not_active Ceased
- 2017-06-19 CN CN201780078132.8A patent/CN110121358A/zh active Pending
- 2017-06-19 TW TW106120457A patent/TW201822790A/zh unknown
- 2017-06-19 JP JP2019531806A patent/JP2020502132A/ja active Pending
- 2017-06-19 TW TW106120454A patent/TWI752044B/zh active
- 2017-06-19 CA CA3047174A patent/CA3047174A1/en not_active Abandoned
- 2017-06-19 CN CN201780078166.7A patent/CN110139668A/zh active Pending
- 2017-06-19 EP EP17880059.5A patent/EP3556380A4/en active Pending
- 2017-06-19 CA CA3046669A patent/CA3046669A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2020512288A5 (https=) | ||
| Wang et al. | Advancement of multi-target drug discoveries and promising applications in the field of Alzheimer's disease | |
| Engelmann et al. | Autologous bone marrow stem cell mobilization induced by granulocyte colony-stimulating factor after subacute ST-segment elevation myocardial infarction undergoing late revascularization: final results from the G-CSF-STEMI (Granulocyte Colony-Stimulating Factor ST-Segment Elevation Myocardial Infarction) trial | |
| Daskalopoulos et al. | Targeting the Wnt/frizzled signaling pathway after myocardial infarction: a new tool in the therapeutic toolbox? | |
| Spahn et al. | Monocytes in sterile inflammation: recruitment and functional consequences | |
| Kumagai et al. | A therapeutic angiogenesis of sustained release of basic fibroblast growth factor using biodegradable gelatin hydrogel sheets in a canine chronic myocardial infarction model | |
| Li et al. | Therapeutic advances in cardiac targeted drug delivery: from theory to practice | |
| Kirby et al. | Population Pharmacokinetics of Sofosbuvir and Its Major Metabolite (gs-331007) in Healthy and HCV infected Adult Subjects: 1106 | |
| JP2020523327A5 (https=) | ||
| Duan et al. | Delivery approaches of gene therapy in hepatocellular carcinoma | |
| Huang et al. | The application of nanoparticles targeting cancer-associated fibroblasts | |
| Shen et al. | Developing a rat model of dilated cardiomyopathy with improved survival | |
| JP2020511413A5 (https=) | ||
| Marrero | Current treatment approaches in HCC | |
| Wang et al. | Targeted delivery of VEGF to treat myocardial infarction | |
| CN110191718A (zh) | 一种预防和治疗组织器官纤维化的方法 | |
| Sindhu et al. | The ameliorating approach of nanorobotics in the novel drug delivery systems: a mechanistic review | |
| Alijani-Ghazyani et al. | Transplantation of umbilical cord-derived mesenchymal stem cells overexpressing lipocalin 2 ameliorates ischemia-induced injury and reduces apoptotic death in a rat acute myocardial infarction model | |
| JP2021530249A5 (https=) | ||
| Sarma et al. | Challenges and Future Directions for Next-Generation Drug Delivery Systems | |
| Jeon et al. | Chemical modulators working at pharmacological interface of target proteins | |
| Sun et al. | Transient overexpression of hPKM2 in porcine cardiomyocytes prevents heart failure after myocardial infarction | |
| Yu et al. | Ultrasound-guided percutaneous portal transplantation of peripheral blood monocytes in patients with liver cirrhosis | |
| O'Connor et al. | A novel cardiac muscle‐derived biomaterial reduces dyskinesia and postinfarct left ventricular remodeling in a mouse model of myocardial infarction | |
| Group | ST-elevation myocardial infarction: New Zealand Management Guidelines, 2013 |